Summary & Overview
HCPCS Level II J0585: OnabotulinumtoxinA Injection, 1 Unit
HCPCS Level II code J0585 denotes one unit of onabotulinumtoxinA supplied for therapeutic injection. Nationally, this drug code is central to billing for botulinum toxin therapies used across multiple neuromuscular and movement disorder indications; accurate coding supports appropriate claim adjudication and clinical documentation for outpatient administration. Major commercial payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare.
Readers will find a concise explanation of what J0585 represents clinically and operationally, how it is used in outpatient therapeutic injection contexts, and the payer landscape relevant to coverage and claim processing. The publication outlines common clinical applications that drive use of onabotulinumtoxinA, links to related procedural codes for chemodenervation services, and highlights common modifiers and coding considerations that commonly appear alongside drug units. The summary also identifies typical provider specialties that order or administer the drug and the usual places of service for infusion or injection. Where input data is incomplete, the document notes that information is not available in the input.
Billing Code Overview
HCPCS Level II code J0585 represents an injectable formulation: Injection, onabotulinumtoxina, 1 unit. This code is used for billing the drug product itself when onabotulinumtoxinA is administered for therapeutic purposes. The service type is drug administration / therapeutic injection, and the typical site of service is the outpatient setting (for example, physician office, POS 11).
Clinical & Coding Specifications
Clinical Context
A patient with focal dystonia (for example, blepharospasm or cervical dystonia) presents to an outpatient physician office (POS 11) for targeted chemodenervation. A neurology or physiatry evaluation documents focal involuntary muscle contractions causing functional impairment. The clinician discusses risks, benefits, and expected onset/duration of effect. On the day of service, the patient is positioned, target muscles are identified by examination (and optional EMG localization if indicated), and onabotulinumtoxinA is reconstituted per manufacturer guidance. The clinician administers one or more injections into the affected muscles and bills for the drug units administered using HCPCS Level II code J0585 (injection, onabotulinumtoxina, 1 unit), along with an appropriate procedure code for the injection service when required. The encounter includes documentation of indication, informed consent, units administered, injection sites, lot number, and any discarded drug amount if applicable.
Coding Specifications
-
Modifiers
-
JW— Use when a portion of the drug is discarded and not administered to any patient; report the discarded units in addition to the units administered when payer policy requires separate reporting. -
59— Use to indicate a Distinct Procedural Service when a separate, identifiable service or procedure is performed on the same day and it is appropriate under payer rules to indicate distinctness from other services billed. -
Associated Provider Taxonomies